Current Olmesartan HCTZ 20-12.5 Recall Status
The latest public data show ongoing voluntary recalls of certain olmesartan medoxomil and hydrochlorothiazide tablets, including the 20-12.5 mg strength, due to nitrosamine impurity concerns. The U.S. Food and Drug Administration maintains a current database of affected NDCs, lot numbers, and recall classifications, which can be reviewed through the agency's recall portal FDA Recalls Database. As of the most recent updates, multiple manufacturers have issued nationwide distribution stops and consumer-level recalls for specific lots that failed impurity testing above acceptable intake limits.
Regulatory filings indicate that the recalls are classified based on the level of health risk, with most entries falling under Class II, meaning temporary or medically reversible adverse health consequences are possible. The FDA's enforcement reports list the specific dosage form, strength, and packaging configurations impacted by the olmesartan HCTZ 20-12.5 recall, allowing pharmacies and distributors to identify and quarantine affected inventory. Companies involved include both originators and generic firms, with the scope of each recall tied to particular manufacturing sites and supply chain lots.
Companies and Regulatory Responses
Major pharmaceutical companies that have issued or are linked to the olmesartan HCTZ 20-12.5 recall include both branded and generic manufacturers, with public notices detailing the names of the recalling firms, NDC numbers, and lot identifiers. The FDA coordinates with these firms to ensure that affected products are removed from the supply chain and that alternative, non-affected lots remain available for patients with hypertension and edema indications.
In parallel, the agency has updated its guidance on nitrosamine impurities in sartan and thiazide combination products, reinforcing testing requirements and acceptable limits for impurities such as NDMA and NDEA. Companies are required to submit field corrective action reports, and the FDA posts inspection findings and warning letters when manufacturing deviations are identified, as documented in the agency's enforcement actions FDA Guidance Documents. Investors tracking the pharmaceutical sector monitor these recalls for potential impacts on market share, litigation exposure, and supply chain resilience.
Market Impact, Patient Guidance, and Financial Considerations
The olmesartan HCTZ 20-12.5 recall has influenced pharmacy inventory management, with some chains and distributors temporarily suspending orders for affected lots and substituting alternative products from unaffected manufacturers. Patients are advised to check their prescription bottles for lot numbers and expiration dates that match the FDA's recall lists, and to contact their pharmacist or prescriber for replacement options if their product is affected.
From a financial perspective, the recall affects short-term revenue for the implicated manufacturers and may shift volume toward competitors with unaffected inventory, altering market dynamics in the cardiovascular generics space. Analysts and institutional investors use SEC filings and company press releases to track the financial impact of such recalls, including any disclosed liabilities, litigation reserves, or remediation costs, as reported in corporate disclosures SEC EDGAR Filings. For the latest public updates on the olmesartan HCTZ 20-12.5 recall, the FDA's drug recall database and the company-specific recall notices remain the primary authoritative sources.